Guess Who Picked Concert Pharmaceuticals Inc. (NYSE:CNCE) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Concert Pharmaceuticals Inc. (NYSE:CNCE) reported that Great Point Partners has picked up 2,101,301 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Great Point Partners to a total of 2,101,301 representing a 9.41% stake in the company.
For those not familiar with the company, Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company’s product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.
A glance at Concert Pharmaceuticals Inc. (NYSE:CNCE)’s key stats reveals a current market capitalization of 357.71 Million based on 22.33 Million shares outstanding and a price at last close of $16.19 share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-05-10, Tung picked up 19,610 at a purchase price of $10.55. This brings their total holding to 538,965 as of the date of the filing.
On the sell side, the most recent transaction saw Hutt unload 22,123 shares at a sale price of $9.81. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Concert Pharmaceuticals Inc. (NYSE:CNCE) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Morgan Stanley is Buying Ophthotech Corp. (NASDAQ:OPHT) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ophthotech Corp. (NASDAQ:OPHT) reported that Morgan Stanley has picked up 10,932,054 of common stock as of 2017-03-08.
The acquisition brings the aggregate amount owned by Morgan Stanley to a total of 10,932,054 representing a 6.1% stake in the company.
For those not familiar with the company, Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.
A glance at Ophthotech Corp. (NASDAQ:OPHT)’s key stats reveals a current market capitalization of 129.27 million based on 35.81 Million shares outstanding and a price at last close of $3.62 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-06-03, Bolte picked up 3,500 at a purchase price of $56.97. This brings their total holding to 6,000 as of the date of the filing.
On the sell side, the most recent transaction saw Bolte unload 6,000 shares at a sale price of $4.83. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ophthotech Corp. (NASDAQ:OPHT) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Reata Pharmaceuticals Inc. (NASDAQ:RETA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported that Rose William has picked up 3,179,427 of common stock as of 2017-03-03.
The acquisition brings the aggregate amount owned by Rose William to a total of 3,179,427 representing a 19.9% stake in the company.
For those not familiar with the company, Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.
A glance at Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s key stats reveals a current market capitalization of 673.95 Million based on 8.31 Million shares outstanding and a price at last close of $28.86 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-30, Traweek picked up 9,392 at a purchase price of $21.72. This brings their total holding to 1,926,034 as of the date of the filing.
On the sell side, the most recent transaction saw Joliff unload 1,031 shares at a sale price of $9.90. This brings their total holding to 19,238.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Reata Pharmaceuticals Inc. (NASDAQ:RETA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Farallon Capital is Buying Radius Health Inc. (NASDAQ:RDUS) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Radius Health Inc. (NASDAQ:RDUS) reported that Farallon Capital has picked up 680,900 of common stock as of 2017-02-28.
The acquisition brings the aggregate amount owned by Farallon Capital to a total of 680,900 representing a 1.6% stake in the company.
For those not familiar with the company, Radius Health, Inc. is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
A glance at Radius Health Inc. (NASDAQ:RDUS)’s key stats reveals a current market capitalization of 1.79 billion based on 43.19 Million shares outstanding and a price at last close of $43.60 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-11-25, Fitzpatrick picked up 100 at a purchase price of $60.60. This brings their total holding to 100 as of the date of the filing.
On the sell side, the most recent transaction saw Ward unload 25,000 shares at a sale price of $62.77. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Radius Health Inc. (NASDAQ:RDUS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Blue Harbour Group is Buying Miragen Therapeutics Inc. (NASDAQ:MGEN) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Miragen Therapeutics Inc. (NASDAQ:MGEN) reported that Boulder Ventures V, L.p. has picked up 1,607,437 of common stock as of 2017-02-24.
The acquisition brings the aggregate amount owned by Boulder Ventures V, L.p. to a total of 1,607,437 representing a 7.5% stake in the company.
For those not familiar with the company, miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discovering and developing innovative microRNA-targeting therapies to improve human health.
A glance at Miragen Therapeutics Inc. (NASDAQ:MGEN)’s key stats reveals a current market capitalization of 297.99 Million based on 21.30million shares outstanding and a price at last close of $13.92 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-11-20, Riccitelli picked up 7,000 at a purchase price of $0.80. This brings their total holding to 345,130 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Miragen Therapeutics Inc. (NASDAQ:MGEN)
as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Calithera Biosciences Inc. (NASDAQ:CALA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Calithera Biosciences Inc. (NASDAQ:CALA) reported that Viking Global has picked up 1,607,936 of common stock as of 2017-02-21.
The acquisition brings the aggregate amount owned by Viking Global to a total of 1,607,936 representing a 7.8% stake in the company.
For those not familiar with the company, Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.
A glance at Calithera Biosciences Inc. (NASDAQ:CALA)’s key stats reveals a current market capitalization of 201.87 million based on 21.82 million shares outstanding and a price at last close of $9.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-16, Adage picked up 500,000 at a purchase price of $3.15. This brings their total holding to 3,635,069 as of the date of the filing.
On the sell side, the most recent transaction saw Hecht unload 970 shares at a sale price of $6.58. This brings their total holding to 8,625.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Calithera Biosciences Inc. (NASDAQ:CALA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Aimmune Therapeutics Inc. (NASDAQ:AIMT) is Attracting Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Aimmune Therapeutics Inc. (NASDAQ:AIMT) reported that Longitude Capital Partners Ii, Llc. has picked up 6,013,134 of common stock as of 2017-02-21.
The acquisition brings the aggregate amount owned by Longitude Capital Partners Ii, Llc. to a total of 6,013,134 representing a 14.2% stake in the company.
For those not familiar with the company, Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.
A glance at Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s key stats reveals a current market capitalization of 1.00 billion based on 50.04 million shares outstanding and a price at last close of $20.07 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-19, Enright picked up 45,440 at a purchase price of $14.15. This brings their total holding to 7,513,134 as of the date of the filing.
On the sell side, the most recent transaction saw Barrowcliffe unload 20,000 shares at a sale price of $25.00. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Aimmune Therapeutics Inc. (NASDAQ:AIMT) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Guess Who Picked Up Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) reported that Great Point Partners has picked up 2,216,216 of common stock as of 2017-02-17.
The acquisition brings the aggregate amount owned by Great Point Partners to a total of 2,216,216 representing a 5.04% stake in the company.
For those not familiar with the company, Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. The Company offers HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). The Company offers Fanapt (iloperidone) for the treatment of schizophrenia. Additionally, its distribution partners launched Fanapt in Israel and Mexico. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. It is indicated for the treatment of CNS Disorders.
A glance at Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s key stats reveals a current market capitalization of 659.20 million based on 43.93 million shares outstanding and a price at last close of $15.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-16, Flynn picked up 3,239 at a purchase price of $8.97. This brings their total holding to 1,103,617 as of the date of the filing.
On the sell side, the most recent transaction saw Baroldi unload 16,300 shares at a sale price of $15.51. This brings their total holding to 54,365.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.